Development and validation of a prediction model for invasive bacterial infections in febrile children at European Emergency Departments: MOFICHE, a prospective observational study.
Anti-Bacterial Agents
/ therapeutic use
Bacteremia
/ diagnosis
Bacterial Infections
/ diagnosis
Biomarkers
/ analysis
C-Reactive Protein
/ metabolism
Child
Child, Preschool
Clinical Decision Rules
Emergency Service, Hospital
/ statistics & numerical data
Europe
/ epidemiology
Female
Fever
/ microbiology
Humans
Inappropriate Prescribing
/ prevention & control
Infant
Male
Meningitis
/ diagnosis
Prospective Studies
Sensitivity and Specificity
epidemiology
therapeutics
Journal
Archives of disease in childhood
ISSN: 1468-2044
Titre abrégé: Arch Dis Child
Pays: England
ID NLM: 0372434
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
22
07
2020
revised:
25
10
2020
accepted:
27
10
2020
pubmed:
20
11
2020
medline:
14
9
2021
entrez:
19
11
2020
Statut:
ppublish
Résumé
To develop and cross-validate a multivariable clinical prediction model to identify invasive bacterial infections (IBI) and to identify patient groups who might benefit from new biomarkers. Prospective observational study. 12 emergency departments (EDs) in 8 European countries. Febrile children aged 0-18 years. IBI, defined as bacteraemia, meningitis and bone/joint infection. We derived and cross-validated a model for IBI using variables from the Feverkidstool (clinical symptoms, C reactive protein), neurological signs, non-blanching rash and comorbidity. We assessed discrimination (area under the receiver operating curve) and diagnostic performance at different risk thresholds for IBI: sensitivity, specificity, negative and positive likelihood ratios (LRs). Of 16 268 patients, 135 (0.8%) had an IBI. The discriminative ability of the model was 0.84 (95% CI 0.81 to 0.88) and 0.78 (95% CI 0.74 to 0.82) in pooled cross-validations. The model performed well for the rule-out threshold of 0.1% (sensitivity 0.97 (95% CI 0.93 to 0.99), negative LR 0.1 (95% CI 0.0 to 0.2) and for the rule-in threshold of 2.0% (specificity 0.94 (95% CI 0.94 to 0.95), positive LR 8.4 (95% CI 6.9 to 10.0)). The intermediate thresholds of 0.1%-2.0% performed poorly (ranges: sensitivity 0.59-0.93, negative LR 0.14-0.57, specificity 0.52-0.88, positive LR 1.9-4.8) and comprised 9784 patients (60%). The rule-out threshold of this model has potential to reduce antibiotic treatment while the rule-in threshold could be used to target treatment in febrile children at the ED. In more than half of patients at intermediate risk, sensitive biomarkers could improve identification of IBI and potentially reduce unnecessary antibiotic prescriptions.
Identifiants
pubmed: 33208397
pii: archdischild-2020-319794
doi: 10.1136/archdischild-2020-319794
pmc: PMC8237171
doi:
Substances chimiques
Anti-Bacterial Agents
0
Biomarkers
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
641-647Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Hum Vaccin Immunother. 2019;15(2):459-469
pubmed: 30273506
BMJ. 2010 Apr 20;340:c1594
pubmed: 20406860
JAMA. 2016 Aug 23-30;316(8):835-45
pubmed: 27552617
J Clin Epidemiol. 2016 Jan;69:245-7
pubmed: 25981519
Pediatrics. 2017 Aug;140(2):
pubmed: 28679639
Pediatrics. 2014 Jun;133(6):e1647-54
pubmed: 24819580
Sci Rep. 2019 Aug 13;9(1):11780
pubmed: 31409879
PLoS Med. 2020 Aug 19;17(8):e1003208
pubmed: 32813708
Stat Methods Med Res. 2018 Jan;27(1):185-197
pubmed: 27460537
Arch Dis Child. 2018 Nov;103(11):1033-1041
pubmed: 29794106
PLoS Med. 2020 Jan 31;17(1):e1003034
pubmed: 32004317
Stat Med. 2004 Aug 30;23(16):2567-86
pubmed: 15287085
BMJ. 2013 Apr 02;346:f1706
pubmed: 23550046
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
Lancet Infect Dis. 2017 Apr;17(4):431-440
pubmed: 28012942
Med Decis Making. 2006 Nov-Dec;26(6):565-74
pubmed: 17099194
Lancet. 2019 Aug 31;394(10200):757-779
pubmed: 31257127
Pediatrics. 2016 Aug;138(2):
pubmed: 27382134
PLoS One. 2015 Mar 18;10(3):e0120012
pubmed: 25785720
BMJ. 2011 Mar 08;342:d1277
pubmed: 21385800
J Clin Epidemiol. 2016 Jun;74:167-76
pubmed: 26772608
BMJ Paediatr Open. 2019 Jun 27;3(1):e000456
pubmed: 31338429
Pediatr Infect Dis J. 2018 May;37(5):387-393
pubmed: 29373477
J Pediatr. 2019 Jan;204:177-182.e1
pubmed: 30297292
Am J Respir Crit Care Med. 2003 Mar 1;167(5):695-701
pubmed: 12433670
Lancet. 2015 Jan 31;385(9966):430-40
pubmed: 25280870
Pediatrics. 2019 Jul;144(1):
pubmed: 31167938
JAMA Pediatr. 2019 Apr 1;173(4):342-351
pubmed: 30776077
Stat Med. 2019 Mar 30;38(7):1276-1296
pubmed: 30357870
Medicine (Baltimore). 2019 Jan;98(2):e13989
pubmed: 30633182
Pediatrics. 2011 Sep;128(3):595-610
pubmed: 21873693
Stat Med. 2016 Jan 30;35(2):214-26
pubmed: 26553135
Lancet Infect Dis. 2019 Apr;19(4):382-391
pubmed: 30827808